A randomised comparison of two inactivated hepatitis A vaccines, Avaxim and Vaqta, given as a booster to subjects primed with Avaxim.
作者： Paul Clarke , Nicholas Kitchin , Frédéric Souverbie
DOI: 10.1016/S0264-410X(01)00195-5
关键词:
摘要: Abstract To investigate whether Vaqta™ may be used as a booster in subjects primed with Avaxim™, 127 adults 6 months previously Avaxim™ were randomised to receive either or booster. Prior the all seropositive. Geometric mean antibody titres increased from 496 7262 mIU/mL 1 month after receiving and 325 5131 Both vaccines well tolerated; 20.3% of experienced local reaction, compared 39.7% those Avaxim™. Systemic reactions reported by 15.6% 14.3%
elsevier.com
sci-hub.se 参考文章(14)
K. Van Herck, P. Beutels, P. Van Damme, M. Beutels, J. Van den Dries, Ph. Briantais, E. Vidor, Mathematical models for assessment of long‐term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines Journal of Medical Virology. ,vol. 60, pp. 1- 7 ,(2000) , 10.1002/(SICI)1096-9071(200001)60:1<1::AID-JMV1>3.0.CO;2-H
Brian L. Wiens, Norman R. Bohidar, Joseph G. Pigeon, James Egan, William Hurni, Leora Brown, Barbara J. Kuter, David R. Nalin, Duration of protection from clinical hepatitis A disease after vaccination with VAQTA. Journal of Medical Virology. ,vol. 49, pp. 235- 241 ,(1996) , 10.1002/(SICI)1096-9071(199607)49:3<235::AID-JMV13>3.0.CO;2-B
Robert Steffen, Risk of hepatitis A in travellers. Vaccine. ,vol. 10, ,(1992) , 10.1016/0264-410X(92)90548-X
Jean Henrik Braconier, Solveig Wennerholm, S.Ragnar Norrby, Comparative immunogenicity and tolerance of Vaqta™ and Havrix™ Vaccine. ,vol. 17, pp. 2181- 2184 ,(1999) , 10.1016/S0264-410X(98)00352-1
Joe P Bryan, Charles H Henry, Ann G Hoffman, Jeannette E South-Paul, Jeffrey A Smith, David Cruess, J.Michael R Spieker, Maria de Medina, Randomized, cross-over, controlled comparison of two inactivated hepatitis A vaccines☆ Vaccine. ,vol. 19, pp. 743- 750 ,(2000) , 10.1016/S0264-410X(00)00301-7
Jane N. Zuckerman, Christopher T. Kirkpatrick, Moses Huang, Immunogenicity and Reactogenicity of Avaxim (160 AU) as Compared with Havrix (1440 EL.U) as a Booster Following Primary Immunization with Havrix (1440 EL.U) against Hepatitis A Journal of Travel Medicine. ,vol. 5, pp. 18- 22 ,(1998) , 10.1111/J.1708-8305.1998.TB00450.X
W. J. Miller, W. Clark, W. Hurni, B. Kuter, T. Schofield, D. Nalin, Sensitive assays for hepatitis a antibodies Journal of Medical Virology. ,vol. 41, pp. 201- 204 ,(1993) , 10.1002/JMV.1890410306
Christian Goilav, Jane Zuckerman, Michael Lafrenz, Emmanuel Vidor, Sabine Lauwers, Christine Ratheau, Grazia Benichou, Arie Zuckerman, Immunogenicity and safety of a new inactivated hepatitis A vaccine in a comparative study. Journal of Medical Virology. ,vol. 46, pp. 287- 292 ,(1995) , 10.1002/JMV.1890460321
Kristi L. Kirschner, In Loring Park JAMA: The Journal of the American Medical Association. ,vol. 271, pp. 28- 28 ,(1994) , 10.1001/JAMA.1994.03510250044029
E. Vidor, B. Fritzell, S. Plotkin, Clinical development of a new inactivated hepatitis a vaccine Infection. ,vol. 24, pp. 447- 458 ,(1996) , 10.1007/BF01713047